极光激酶B抑制剂的研究进展  

Research progress on aurora kinase B inhibitors

作　　者：马澜婧 杜海琛 张百红 MA Lan-jing;DU Hai-chen;ZHANG Bai-hong(Department of Oncology,The 940th Hospital of Joint Logistics Support Force of People’s Liberation Army,Lanzhou 730050,China)

机构地区：[1]中国人民解放军联勤保障部队第940医院肿瘤科,甘肃兰州730050

出　　处：《现代药物与临床》2023年第10期2620-2630,共11页Drugs & Clinic

基　　金：甘肃省自然科学基金资助项目(22JR5RA021)。

摘　　要：极光激酶是维持细胞基因组完整性的关键丝氨酸/苏氨酸有丝分裂调节激酶,由3个成员极光激酶A、B、C组成,其中极光激酶B在有丝分裂中起着至关重要的作用。极光激酶B在多种恶性肿瘤中过表达,故极光激酶B被作为有吸引力的抗癌药物靶点被广泛研究,目前已经开发了多种靶向极光激酶B的小分子抑制剂。介绍了极光激酶B特异性抑制剂、进入临床试验阶段的泛极光激酶抑制剂等的研究进展,希望为极光激酶B抑制剂的开发和临床使用提供参考。Aurora kinase is a key serine/threonine mitotic regulatory kinase that maintains the integrity of the cell genome,consisting of three members,aurora kinases A,B,and C.Aurora kinase B plays a crucial role in mitosis.Over-expression of aurora kinase B is frequently observed in various malignant tumors,so aurora kinase B has been widely studied as an attractive anticancer drug target.Currently,various small molecule inhibitors targeting aurora kinase B have been developed.This article introduces the research progress of aurora kinase B specific inhibitors and pan-aurora kinase inhibitors entering the clinical trial stage,hoping to provide reference for the development and clinical use of aurora kinase B inhibitors.

关 键 词：极光激酶 极光激酶B 有丝分裂 极光激酶B抑制剂 泛极光激酶抑制剂 

分 类 号：R961[医药卫生—药理学]